경피적 풍선 척추성형술 시장 : 예측(2023-2028년)

The kyphoplasty market was evaluated at US$799.574 million in 2021 and will grow at a CAGR of 5.48% to be worth US$1,161.548 million by 2028.

Kyphoplasty is a medical procedure employed to alleviate pain caused by compression fractures in the spine. These fractures occur when all or a portion of a spine bone collapses, leading to discomfort and reduced spinal stability. By undergoing kyphoplasty, patients can experience relief from pain and improved spinal function. Kyphoplasty finds applications in the restoration of vertebral alignment and treatment of spinal fractures. The end users of kyphoplasty include hospitals & clinics as well as ambulatory surgical centers.

The rise in the healthcare sector bolsters the kyphoplasty market growth.

Kyphoplasty is a safe and effective procedure to treat painful vertebral compression fractures caused by conditions like osteoporosis and traumatic injuries. These fractures often result in severe pain and reduced mobility, and kyphoplasty offers a minimally invasive solution to stabilize the fractured vertebrae, restore vertebral height, and alleviate pain. The expansion of healthcare coverage and improved access to medical services driven by government initiatives contribute to the overall growth and development of the healthcare industry. For instance, in March 2022, Spine BioPharma secured a significant $14 million series B round of funding, earmarked to bolster its injectable treatment for degenerative disc disease.

Increasing prevalence of osteoporosis drives the kyphoplasty market expansion.

Kyphoplasty is used as a treatment for osteoporosis-related vertebral compression fractures, which occur due to weakened bones in individuals with osteoporosis. In kyphoplasty, a minimally invasive procedure, a balloon is inserted into the fractured vertebra and inflated to create a cavity, followed by the injection of bone cement to stabilize the fracture and restore vertebral height. Osteoporosis is increasing primarily due to factors such as an aging population, sedentary lifestyles, and inadequate calcium and vitamin D intake. According to the Natural Library of Medicine, the projected annual number of osteoporotic fractures in the EU27+2 region is anticipated to rise significantly by 1.06 million, reaching a total of 5.05 million cases in 2034, compared to 4.28 million cases in 2019.

Minimally invasive nature drives kyphoplasty market growth.

Kyphoplasty stands out as a less invasive alternative to conventional surgical methods for treating vertebral fractures. This procedure offers several advantages, including shorter hospital stays, quicker recovery times, and fewer post-operative complications, making it a compelling choice for patients and healthcare providers alike. With the entire process typically taking less than an hour, kyphoplasty presents an appealing solution for effectively addressing spine-related issues, improving patient outcomes, and reducing the burden on healthcare facilities. Its minimally invasive nature makes it a favorable option for those seeking a less disruptive and more efficient treatment approach for painful vertebral fractures and kyphosis.

North America is expected to dominate the kyphoplasty market.

North America is projected to hold a significant share of the kyphoplasty market primarily due to the escalating incidence of traumatic spinal injuries coupled with government investments and initiatives. For instance, in January 2022, under the leadership of UBC researchers, a groundbreaking project with funding of $24 million had been initiated to advance the treatment of spinal cord injuries. Also, according to the National Spinal Cord Injury Statistical Center in 2021, the United States witnessed an annual incidence of approximately 54 cases of traumatic spinal cord injury (SCI) per one million people, resulting in approximately 18,000 new SCI cases each year. This figure highlights the significant impact of traumatic spinal cord injuries on the population, emphasizing the need for effective treatments like kyphoplasty.

Risks involved in kyphoplasty restrain the kyphoplasty market growth.

The risks associated with the procedure such as infection, bleeding, increased back pain, and the possibility of numbness, or weakness due to nerve damage are posing a challenge to the overall market growth. Moreover, there are notable concerns regarding potential allergic reactions to chemicals utilized with X-rays for guidance and the risk of unintended cement leakage from its intended position. These risks may deter some patients from opting for kyphoplasty, impacting market growth despite its proven effectiveness in treating vertebral fractures and kyphosis.

Key Developments

• August 2021: IZI Medical launched Vertefix HV Cement, providing physicians with an advanced solution to monitor and regulate the flow of cement during vertebroplasty and kyphoplasty procedures. This innovative product incorporates variable-sized barium particles with high viscosity, enabling precise tracking and control of cement distribution. As a result, Vertefix HV Cement significantly enhances procedural outcomes and ensures greater safety for patients, making it a valuable addition to the medical community's arsenal in treating related conditions effectively and with improved precision.
• May 2020: Medtronic plc introduced the Kyphon Assist Directional Cannula in the United States, complementing its balloon kyphoplasty (BKP) products to address vertebral compression fractures arising from osteoporosis, cancer, or benign lesions. This novel device empowers physicians with enhanced control during bone tamp inflation and height restoration compared to conventional balloon kyphoplasty cannulas. The Kyphon Assist Directional Cannula represents a significant advancement in the treatment of vertebral fractures, enabling more precise and effective procedures for those suffering from these conditions.

Company Products

• AVAflex Balloon System: Stryker's AVAflex balloon system offers a simplified and effective approach to treating vertebral compression fractures (VCFs) while achieving bipedicular results with a unipedicular approach. With its multiple balloon sizes and needle gauge options, AVAflex is designed to cater to various physician preferences and patient requirements. The system's curved coaxial needle allows for precise cement placement, ensuring an optimal fill within the vertebral body. With these advanced features, AVAflex empowers healthcare professionals to streamline VCF treatments, providing targeted and efficient solutions for improved patient outcomes.
• KYPHON BALLOON KYPHOPLASTY PLATFORM: Medtronic's Kyphon is a groundbreaking innovation, offering several advantages over previous technologies. With a maximum rated inflation pressure of 700 psi, the balloons provide higher pressure capabilities compared to the previous 400 psi balloons. The cement resistance technique enables physicians to deliver cement through one cannula while maintaining fracture reduction by keeping the contralateral balloon inflated. Additionally, the Kyphon cement delivery system allows for cement delivery from up to 48 inches away from the radiation source during a kyphoplasty procedure.

Segmentation

By Product

• Balloon Catheters
• Bone Access Devices
• Cement Application Products
• Bone Cement
• Cement Mixing Systems
• Instruments

By Application

• Vertebral Alignment Restoration
• Spinal Fractures
• Kyphosis

By End-Use

• Hospitals & Clinics
• Ambulatory Surgical Centers

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. KYPHOPLASTY MARKET, BY PRODUCT

• 5.1. Introduction
• 5.2. Balloon Catheters
• 5.3. Bone Access Devices
• 5.4. Cement Application Products
• 5.5. Bone Cement
• 5.6. Cement Mixing Systems
• 5.7. Instruments

6. KYPHOPLASTY MARKET, BY APPLICATION

• 6.1. Introduction
• 6.2. Vertebral Alignment Restoration
• 6.3. Spinal Fractures
• 6.4. Kyphosis

7. KYPHOPLASTY MARKET, BY END-USE

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Ambulatory Surgical Centers

8. KYPHOPLASTY MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Stryker
• 10.2. Medtronic Inc.
• 10.3. MicroPort Scientific Corporation
• 10.4. DePuy Synthes (Johnson & Johnson Services Inc.)
• 10.5. IZI Medical Products
• 10.6. Merit Medical Systems
• 10.7. Joimax GmbH
• 10.8. G21 S.r.l.
• 10.9. Joline GmbH & Co. KG
• 10.10. Hensler Surgical Products